Ozette, a startup using AI to enhance immune system monitoring for use in cancer treatment decisions, raises a $6M seed round led by Madrona Venture Group
Context & Ripple Effects
Ozette's $6M seed lands five days after Immunai's $60M Series A for AI-driven immune-system analysis — two startups attacking the same biological data layer from different funding stages in the same month, which signals investors see immune profiling as a distinct category rather than a niche. The broader arc in the related coverage is AI moving deeper into oncology decisions: Ibex on AI-powered cancer diagnostics, Ezra on AI full-body MRI screening, and Imagene on biopsy-image biomarker detection have all raised across 2021–2024.
First-order effects
- Ozette now has capital to build out its immune-monitoring platform for treatment decisions, with Madrona's lead giving it a Pacific Northwest anchor investor at the seed stage.
Second-order effects
- Ozette's seed-stage entry against Immunai's $60M war chest forces the category toward differentiation — treatment-decision support versus discovery — before either reaches clinical buyers, and pharma customers gain a second vendor to benchmark pricing against.
Third-order effects
- If the pattern holds, immune-system data becomes a standard input to oncology workflows alongside imaging and pathology AI, pushing hospitals and drug developers to integrate multiple AI vendors rather than a single diagnostic provider.
The trend: AI oncology funding is stratifying by clinical touchpoint — screening, diagnostics, biopsy imaging, and now immune monitoring — with each layer attracting dedicated venture capital.